Navigation Links
Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
Date:5/19/2009

clude, among other things, statements regarding clinical trials, regulatory approvals, competitive offerings and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to al
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
2. Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientifics TAXUS(R) Liberte(R) Stent
3. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
4. Clinical Data Reinforce Safety and Efficacy of Boston Scientifics Two Drug- Eluting Stent Platforms
5. New England Journal of Medicine Publishes Results from Boston Scientifics Landmark SYNTAX(TM) Trial
6. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
7. Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
8. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
9. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
10. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
11. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ... commercialization of innovative therapies for the treatment of acute ... Morris , chief financial officer  will be participating in ... as follows: Mizuho Third Annual Healthcare Corporate ... Berkshire Place, New York ...
(Date:4/30/2015)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider ... today announced results for its first quarter ended March ... first quarter of 2015 was $116.2 million, up $14.5 ... and down $5.3 million or 4.4% from the fourth ... income as reported in accordance with U.S. generally accepted ...
(Date:4/30/2015)... April 30, 2015   Regulus Therapeutics Inc . ... discovery and development of innovative medicines targeting microRNAs, today ... for the quarter ended March 31, 2015 on Thursday, ... Regulus will host a conference call ... pm Eastern Daylight Time to discuss its first quarter ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3
... April 14, 2011 Transgenomic, Inc. (OTC/BB: TBIO) announced ... of the BRAF and PIK3CA genes. These ... K-RAS , expanding Transgenomic,s range of its proprietary SURVEYOR Scan ... K-RAS , BRAF , and PIK3CA ) are widely ...
... Nev., April 14, 2011 Sanare, LLC, a ... with diabetes, announced today the launch of its ... BrightSky is the backbone of Sanare,s ... health plans. The offering includes personalized access to ...
Cached Medicine Technology:Transgenomic, Inc. Expands SURVEYOR® Scan Product Line With BRAF and PIK3CA Mutation Detection Kits 2Transgenomic, Inc. Expands SURVEYOR® Scan Product Line With BRAF and PIK3CA Mutation Detection Kits 3Transgenomic, Inc. Expands SURVEYOR® Scan Product Line With BRAF and PIK3CA Mutation Detection Kits 4Sanare Launches BrightSky, a New Consumer Brand Serving People Living With Diabetes 2
(Date:5/3/2015)... 03, 2015 SpineFrontier, a Less Exposure ... FDA to produce and market their new sacroiliac joint ... used in outpatient settings and is compatible with both ... approach has been extensively researched and refined by SpineFrontier, ... use this approach in conjunction with a sacroiliac joint ...
(Date:5/3/2015)... May 03, 2015 HealthPostures, a ... solutions, announces its appearance at the , May 5 ... that HealthPostures will exhibit at the conference include its ... sit stand solutions is the 6100 TaskMate Executive. Features ... control, an adjustable keyboard tray, extended platform work surface ...
(Date:5/2/2015)... Ticket Down has secured additional inventories of authentic ... today, Saturday, May 2nd at the MGM Grand Garden Arena ... to secure tickets for both the actual fight and various ... wanted for more than five years was finally been agreed ... inside the ring to fight Manny “Pac-Man” Pacquiao in what ...
(Date:5/2/2015)... May 02, 2015 “ ActOn ” was ... takes a look at the latest and coolest applications on ... host of AppWatch and technology expert, conducted the app review ... get connected with organizations to make a difference. , In ... very few things that aren’t about money, which is why ...
(Date:5/2/2015)... NY (PRWEB) May 02, 2015 It’s ... a deadly natural disaster strikes anywhere on this planet, ... leverage human sympathy and compassion for their own personal ... States Computer Emergency Readiness Team) issued an alert ... “of potential email scams citing the earthquake in Nepal. ...
Breaking Medicine News(10 mins):Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4
... When you check into a hospital, the odds are one ... of antibiotic-resistant bacteria as a result of your stay. That ... todays hospitals despite the best efforts of the medical profession. ... deaths per year., Now, a sophisticated new mathematical model has ...
... for,Plastination commends ABC,s 20/20 for its investigation on ... exhibitions. The program served to,inform and educate the ... of bodies used in anatomical exhibitions in particular., ... clarify two vague,statements made by anatomist, Dr. Gunther ...
... survival rates to younger cases , , FRIDAY, Feb. 15 ... transplantation and have good outcomes, and age should not ... a new study says. , Researchers at the University ... of 48 UCLA patients between the ages of 65 ...
... Canadian scientists are finding that out of sight, out of ... the chemicals in our waters. Substances that we use everyday ... they can impact aquatic life and possibly ourselves. , ... of the 30,000 or so chemicals used commercially in the ...
... Premier Exhibitions Inc.,(Nasdaq: PRXI ) today posted ... to an expected 20/20 broadcast that is purported ... to its controversial and,highly successful bodies exhibitions., ... TV,s 20/20 has,chosen to air a segment that ...
... 15 IDEXX Laboratories,Inc. (Nasdaq: IDXX ), announced ... by the Company of an additional four million,shares of ... will be made in the open market or in ... shares remaining as of,December 31, 2007, under a previous ...
Cached Medicine News:Health News:Math model identifies key to controlling epidemic 2Health News:Math model identifies key to controlling epidemic 3Health News:Specimens in BODY WORLDS Exhibitions Stem Primarily from German Body Donation Program 2Health News:Good Outcomes Possible for Older Lung Transplant Patients 2Health News:New findings on emerging contaminants 2Health News:New findings on emerging contaminants 3Health News:New findings on emerging contaminants 4Health News:New findings on emerging contaminants 5Health News:An Open Letter to 20/20 and the Shareholders of Premier Exhibitions, Inc. 2Health News:An Open Letter to 20/20 and the Shareholders of Premier Exhibitions, Inc. 3
Straight shafts with 6 mm tying platform and crisscross serrated tips. Round knurled handle with polished finish. Overall length 4.5 inches....
Curved shafts and tips with 5.5 mm tying platform. 0.3 mm gap at platform heel. True round knurled handle in closed position with polished finish. Overall length 4.3 inches....
Ultra-fine tying platform with round knurled handle for fingertip rotational control. Straight shafts. Overall length 3.9 inches....
5 mm tying platform. Round knurled handle with dull finish. Straight shafts. Overall length 3.9 inches....
Medicine Products: